|
1
|
Doherty GJ, Petruzzelli M, Beddowes E,
Ahmad SS, Caldas C and Gilbertson RJ: Cancer treatment in the
genomic Era. Annu Rev Biochem. 88:247–280. 2019.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Mano H: Cancer genomic medicine in Japan.
Proc Jpn Acad Ser B Phys Biol Sci. 96:316–321. 2020.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Foundation for Promotion of Cancer
Research. Cancer Statistics in Japan. Available at: https://ganjoho.jp/public/qa_links/report/statistics/pdf/cancer_statistics_2023_fig_E.pdf.
Published 2023. Accessed 11 November, 2023.
|
|
4
|
Wu L and Qu X: Cancer biomarker detection:
Recent achievements and challenges. Chem Soc Rev. 44:2963–2997.
2015.PubMed/NCBI View Article : Google Scholar
|
|
5
|
U.S. Food & Drug. Companion
Diagnostics. 2018. Available at: https://www.fda.gov/medical-devices/in-vitro-diagnostics/companion-diagnostics.
Accessed Dec 23 2024.
|
|
6
|
Shirota H, Komine K, Takahashi M,
Takahashi S, Miyauchi E, Niizuma H, Tada H, Shimada M, Niihori T,
Aoki Y, et al: Clinical decisions by the molecular tumor board on
comprehensive genomic profiling tests in Japan: A retrospective
observational study. Cancer Med. 12:6170–6181. 2023.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Constâncio V, Nunes SP, Henrique R and
Jerónimo C: DNA methylation-based testing in liquid biopsies as
detection and prognostic biomarkers for the four major cancer
types. Cells. 9(624)2020.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Motoi N and Yatabe Y: Lung cancer
biomarker tests: The history and perspective in Japan. Transl Lung
Cancer Res. 9:879–886. 2020.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Sekine M, Nishino K and Enomoto T: BRCA
genetic test and risk-reducing salpingo-oophorectomy for hereditary
breast and ovarian cancer: State-of-the-art. Cancers (Basel).
13(2562)2021.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Sunakawa Y, Nakamura M, Ishizaki M,
Kataoka M, Satake H, Kitazono M, Yanagisawa H, Kawamoto Y,
Kuramochi H, Ohori H, et al: RAS mutations in circulating tumor DNA
and clinical outcomes of rechallenge treatment with anti-EGFR
antibodies in patients with metastatic colorectal cancer. JCO
Precis Oncol. 4:898–911. 2020.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Ikoma T, Shimokawa M, Kotaka M, Matsumoto
T, Nagai H, Boku S, Shibata N, Yasui H and Satake H: Clinical and
prognostic features of patients with detailed RAS/BRAF-mutant
colorectal cancer in Japan. BMC Cancer. 21(518)2021.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Shimozaki K, Hayashi H, Tanishima S, Horie
S, Chida A, Tsugaru K, Togasaki K, Kawasaki K, Aimono E, Hirata K,
et al: Concordance analysis of microsatellite instability status
between polymerase chain reaction based testing and next generation
sequencing for solid tumors. Sci Rep. 11(20003)2021.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Medical Data Vision Co., Ltd. About MDV
Database. 2024. Available at: https://en.mdv.co.jp/about-mdv-database/mdv-database-overview/.
Accessed Feb 2, 2025.
|
|
14
|
Berardinelli GN, Durães R, Mafra da Costa
A, Bragagnoli A, Antônio de Oliveira M, Pereira R,
Scapulatempo-Neto C, Guimarães DP and Reis RM: Association of
microsatellite instability (MSI) status with the 5-year outcome and
genetic ancestry in a large Brazilian cohort of colorectal cancer.
Eur J Hum Genet. 30:824–832. 2022.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Hasan S, Renz P, Wegner RE, Finely G, Raj
M, Monga D, McCormick J and Kirichenko A: Microsatellite
instability (MSI) as an independent predictor of pathologic
complete response (PCR) in locally advanced rectal cancer: A
National cancer database (NCDB) analysis. Ann Surg. 271:716–723.
2020.PubMed/NCBI View Article : Google Scholar
|
|
16
|
National Comprehensive Cancer Network.
NCCN Clinical Practice Guidelines in Oncology: Rectal Cancer.
Available at: https://www.nccn.org/professionals/physician_gls/pdf/rectal.pdf.
Published 2018. Accessed 11 Nov, 2023.
|
|
17
|
Garcia-Carbonero R, González Astorga B,
Vidal Tocino R, Contreras Toledo D, Pericay C, Fernández Montes A,
Falcó E, González Cordero M, Reina Zoilo JJ, Alonso V, et al:
Real-world study on microsatellite instability and mismatch repair
deficiency testing patterns among patients with metastatic
colorectal cancer in Spain. Clin Transl Oncol. 26:864–871.
2024.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Dhimal T, Colugnati F, Hilty Chu BK, Loria
A, Cupertino P, Mulkerin D and Fleming FJ: Mismatch repair and
microsatellite testing for individuals with colorectal cancer. JAMA
Oncol. 10:1593–1595. 2024.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Horie S, Saito Y, Kogure Y, Mizuno K, Ito
Y, Tabata M, Kanai T, Murakami K, Koya J and Kataoka K: Pan-cancer
comparative and integrative analyses of driver alterations using
Japanese and International genomic databases. Cancer Discov.
14:786–803. 2024.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Kelkar SS, Prabhu VS, Zhang J, Ogando YM,
Roney K, Verma RP, Miles N and Marth C: Real-world prevalence of
microsatellite instability testing and related status in women with
advanced endometrial cancer in Europe. Arch Gynecol Obstet.
309:2833–2841. 2024.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Chen Y, Lubinga SJ, Williams T, Carlson JJ
and Ramsey S: Real-world molecular testing rates and patterns in
patients with primary advanced or recurrent endometrial cancer in
the United States. JCO Precis Oncol. 9(e2400815)2025.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Japan Society of Clinical Oncology.
Guidelines for Cancer Treatment: Genomic Medicine. 2022. Available
at: http://www.jsco-cpg.jp/precision-medicine/guideline/#cq02-1.
Accessed Jan 23, 2025 (In Japanese).
|
|
23
|
Fujiyoshi K, Yamamoto G, Takahashi A, Arai
Y, Yamada M, Kakuta M, Yamaguchi K, Akagi Y, Nishimura Y, Sakamoto
H and Akagi K: High concordance rate of KRAS/BRAF mutations and
MSI-H between primary colorectal cancer and corresponding
metastases. Oncol Rep. 37:785–792. 2017.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Japan Society of Clinical Oncology.
Treatment Guidelines for Colorectal Cancer. 2020. Available at:
http://www.jsco-cpg.jp/colorectal-cancer/. Accessed
Feb 4, 2025 (In Japanese).
|
|
25
|
Akagi K, Oki E, Taniguchi H, Nakatani K,
Aoki D, Kuwata T and Yoshino T: Real-world data on microsatellite
instability status in various unresectable or metastatic solid
tumors. Cancer Sci. 112:1105–1113. 2021.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Japanese Gastric Cancer Association.
Japanese gastric cancer treatment guidelines 2021 (6th edition).
Gastric Cancer. 26:1–25. 2023.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Japan Society of Gynecologic Oncology.
Uterine Cancer Treatment Guidelines: Chapter 4: Treatment
guidelines for unresectable, advanced, or recurrent cancer. 2023.
Available at: https://jsgo.or.jp/guideline/taiganguide2023.html.
Accessed on Feb 1, 2025 (In Japanese).
|
|
28
|
Japan Society of Gynecologic Oncology.
Ovarian, Fallopian Tube, and Peritoneal Cancer Treatment
Guidelines. 2020. Available at: https://jsgo.or.jp/guideline/ransou2020.html. Accessed
on Feb 1, 2025 (In Japanese).
|
|
29
|
Li K, Luo H, Huang L, Luo H and Zhu X:
Microsatellite instability: A review of what the oncologist should
know. Cancer Cell Int. 20(16)2020.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Sato Y, Okamoto K, Kawano Y, Kasai A,
Kawaguchi T, Sagawa T, Sogabe M, Miyamoto H and Takayama T: Novel
Biomarkers of Gastric Cancer: Current Research and Future
Perspectives. J Clin Med. 12(4646)2023.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Okoye C, Emeasoba C, Obialo-Ibeawuchi C,
Olanipekun NL and Amaechi U: Too late to test: Real-world impact of
MSI/MMR testing delays on survival and treatment in colorectal
cancer. J Natl Compr Canc Netw. 24:BPI26–006. 2026.PubMed/NCBI View Article : Google Scholar
|
|
32
|
AstraZeneca. Lynparza approved in Japan
for 1st-line maintenance therapy in BRCA-mutated advanced ovarian
cancer. 2019. Available at: https://www.astrazeneca.com/media-centre/press-releases/2019/lynparza-approved-in-japan-for-1st-line-maintenance-therapy-in-brca-mutated-advanced-ovarian-cancer-19062019.html#.
Accessed on Feb 1, 2025.
|
|
33
|
Huepenbecker SP, Wright JD, Downer MK,
Incerti D, Luhn P, Dolado I, Bastiere-Truchot L, Lin YG, Chan JK
and Meyer LA: Temporal patterns and adoption of germline and
somatic BRCA testing in ovarian cancer. Obstet Gynecol.
140:758–767. 2022.PubMed/NCBI View Article : Google Scholar
|
|
34
|
AstraZeneca. Lynparza approved in Japan
for the treatment of advanced ovarian, prostate and pancreatic
cancers. 2020. Available at: https://www.astrazeneca.com/media-centre/press-releases/2020/lynparza-approved-in-japan-for-three-cancers.html#.
Accessed Feb 1, 2025.
|
|
35
|
Veljovich DS, Penson RT, Birrer MJ, Luo L,
Pyrih N, Pack S, Iu C and Hada M: Real-world biomarker testing,
treatment patterns and outcomes in a US cohort of patients with
advanced ovarian cancer. J Clin Oncol. 42 (Suppl
16)(S5571)2024.
|
|
36
|
Oda K, Aoki D, Tsuda H, Nishihara H,
Aoyama H, Inomata H, Shimada M and Enomoto T: Japanese nationwide
observational multicenter study of tumor BRCA1/2 variant testing in
advanced ovarian cancer. Cancer Sci. 114:271–280. 2023.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Myriad Genetics Inc. Breakthrough HRD
testing for optimizing ovarian cancer treatment. 2025. Available
at: https://myriad.com/genetic-tests/mychoicecdx-tumor-test/#:~:text=MyChoice%20CDx%20is%20the%20only%20FDA-approved%20homologous%20recombination,therapy%20in%20both%20early%20and%20late-line%20settings.%202.
Accessed Feb 1, 2025.
|
|
38
|
Golan T, Hammel P, Reni M, Van Cutsem E,
Macarulla T, Hall MJ, Park JO, Hochhauser D, Arnold D, Oh DY, et
al: Maintenance olaparib for germline BRCA-mutated metastatic
pancreatic cancer. N Engl J Med. 381:317–327. 2019.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Olmos D, Lorente D, Alameda D, Cattrini C,
Romero-Laorden N, Lozano R, Lopez-Casas PP, Jambrina A, Capone C,
Vanden Broecke AM, et al: Treatment patterns and outcomes in
metastatic castration-resistant prostate cancer patients with and
without somatic or germline alterations in homologous recombination
repair genes. Ann Oncol. 35:458–472. 2024.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Naito Y, Aburatani H, Amano T, Baba E,
Furukawa T, Hayashida T, Hiyama E, Ikeda S, Kanai M, Kato M, et al:
Clinical practice guidance for next-generation sequencing in cancer
diagnosis and treatment (edition 2.1). Int J Clin Oncol.
26:233–283. 2021.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Marcus L, Lemery SJ, Keegan P and Pazdur
R: FDA approval summary: Pembrolizumab for the treatment of
microsatellite instability-high solid tumors. Clin Cancer Res.
25:3753–3758. 2019.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Febbo PG, Allo M, Alme EB, Cuyun Carter G,
Dumanois R, Essig A, Kiernan E, Kubler CB, Martin N, Popescu MC and
Leiman LC: Recommendations for the Equitable and Widespread
Implementation of Liquid Biopsy for Cancer Care. JCO Precis Oncol.
8(e2300382)2024.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Pascual J, Attard G, Bidard FC, Curigliano
G, De Mattos-Arruda L, Diehn M, Italiano A, Lindberg J, Merker JD,
Montagut C, et al: ESMO recommendations on the use of circulating
tumour DNA assays for patients with cancer: A report from the ESMO
precision medicine working group. Ann Oncol. 33:750–768.
2022.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Yatabe Y, Watanabe R, Kotera Y, Yasuoka S
and Ennishi D: Nationwide real-world usage of blood-based (Liquid)
biomarker testing in Japan. Cancer Sci. 116:3113–3124.
2025.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Ohtsu A, Goto K and Yoshino T: Improvement
of patient care using cancer genomic profiling:
SCRUM-/CIRCULATE-Japan experience. Proc Jpn Acad Ser B Phys Biol
Sci. 99:241–253. 2023.PubMed/NCBI View Article : Google Scholar
|
|
46
|
Sawada K, Nakayama K, Nakamura K,
Yoshimura Y, Razia S, Ishikawa M, Yamashita H, Ishibashi T, Sato S
and Kyo S: Clinical outcomes of genotype-matched therapy for
recurrent gynecological cancers: A single institutional experience.
Healthcare (Basel). 9(1395)2021.PubMed/NCBI View Article : Google Scholar
|
|
47
|
Sato Y, Okada Y, Fujino Y, Kawaguchi T,
Kida Y, Mitsui Y, Tanaka H, Tomonari T, Kitamura S, Okamoto K, et
al: Clinical outcomes of comprehensive genomic profiling tests for
gastrointestinal cancers: Experience from Tokushima University
Hospital. J Med Invest. 70:154–159. 2023.PubMed/NCBI View Article : Google Scholar
|
|
48
|
Kawada T, Shim SR, Quhal F, Rajwa P,
Pradere B, Yanagisawa T, Bekku K, Laukhtina E, von Deimling M, Teoh
JY, et al: Diagnostic accuracy of liquid biomarkers for clinically
significant prostate cancer detection: A systematic review and
diagnostic meta-analysis of multiple thresholds. Eur Urol Oncol.
7:649–662. 2024.PubMed/NCBI View Article : Google Scholar
|
